Aw-Poster-Pongsak Pirom-0629
Poster #0629 HEPATITIS B VIRUS DNA LEVEL CHANGES IN HBeAg+ PREGNANT WOMEN RECEIVING TDF FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION IRD-CMU PHPT CROIConference on Retroviruses Nicole Ngo-Giang-Huong1, Nicolas Salvadori2, Woottichai Khamduang2, Tim R. Cressey2, Linda J. Harrison3, Luc Decker1, Camlin Tierney3, Jullapong Achalapong4, and Opportunistic Infections Trudy V. Murphy5, Noele Nelson5, George K. Siberry6, Raymond T. Chung7, Stanislas Pol8, Gonzague Jourdain1, for the iTAP study group 1IRD, Chiang Mai, Thailand, 2Chiang Mai University, Chiang Mai, Thailand, 3Harvard University, Boston, MA, USA, 4Chiangrai Prachanukroh Hospital, Chiang Rai, Thailand, 5CDC, Atlanta, GA, USA, 6USAID, Arlington, VA, USA, 7Massachusetts General Hospital, Boston, MA, USA, 8Cochin Hospital, Paris, France Background HBV DNA load measurements • 12% (19 of 161) did not achieve 5.3 log10 IU/ml at delivery; References • Population: all women assigned to the TDF arm + a randomly the median (range) HBV DNA for these women was 8.3 • High hepatitis B virus (HBV) DNA levels and positive hepatitis (7.1 to 9.1) log IU/mL at baseline, 7.4 (4.7 to 8.6) at • Sarin SK, Kumar M, Lau GK, et al. Asian-Pacific clinical practice guidelines on selected subset of 50 women assigned to the placebo arm 10 B e antigen (HBeAg-an indicator of rapid viral replication and 32-weeks, 7.0 (3.9 to 8.5) at 36 weeks and 7.8 (5.3 to 8.9) the management of hepatitis B: a 2015 update. Hepatol Int 2016;10:1-98. • European Association for the Study of the Liver. Electronic address eee, high level of HBV DNA) are the main markers of risk for • Timing: at baseline (28 weeks gestation), at Weeks 32 and at delivery.
[Show full text]